Investigation of relationship between nesfatin's, chemerin's, apelin's levels and insulin resistance and metabolic syndrome in Polycystic Ovary Syndrome patients

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common gynecological endocrinopathies. In the literature, many studies support the involvement of IR (insulin resistance) and some adipokines in the pathophysiology of PCOS. In our study, we aimed to investigate the relationships of apelin, chemerin, nesfatin, IR, and MS (metabolic syndrome) to help clarify the pathophysiology of PCOS. We included 120 people in our prospective cohort study. We divided these 120 cases into three equal groups: a control group of healthy participants and two case groups of participants suffering from PCOS with a BMI below 30 and above 30. We conducted this study in a tertiary hospital between January 2014 and July 2014. We investigated the study groups in terms of demographic information, biochemical values, hormonal parameters, apelin, chemerin, and nesfatin values, and the relationships between MS and IR. Apelin, chemerin, and nesfatin values were 0.233±0.027 ng/dl, 232.79±221.87 ng/dl, and 2.11±1.27 ng/dl in the control group. These values were 0.304±0.093 ng/dl, 313.57±379.04 ng/dl, and 0.85±0.91 ng/dl in the nonobese PCOS patient group, respectively. The same parameters were 0.304±0.093 ng/dl, 344.31±386.23 ng/dl, and 0.74±1.42 ng/dl in the obese PCOS patient group. The HOMA-IR values of the groups were 1.79 ± 0.68, 3.61 ± 5.45, and 4.58 ± 4.39, respectively. The distribution of cases diagnosed with MS within the groups was 0%, 10%, and 17.5%, respectively. We compared all these statistically significant results (p<0.005). The fact that blood nesfatin levels are significantly lower and apelin and chemerin levels are significantly higher in PCOS patients suggests that the synthesis and secretion of these adipokines are effective in the mechanism of the disease. The development of MS. Comprehensive prospective studies are needed to clarify this situation.

Keywords

• apelin
• chemerin
• HOMA-IR
• metabolic syndrome
• nesfatin
• polycystic ovary syndrome

References

1. 1. Hashemipour M, Faghihimani S, Zolfaghary B, Hovsepian S, Ahmadi F, Haghighi S. Prevalence of polycystic ovary syndrome in girls aged 14-18 years in Isfahan, Iran. Horm Res 2004;62:278-282.
2. 2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25.
3. 3. Speroff L. Anovulation and Polycystic ovary. Speroff L Fritz M.A. (editors). Clinical Gynecologic Endocrinology and Infertility. 6th ed. Philadelphia Pa, Lippincott Williams & Wilkins. 2005:465-491.
4. 4. Bełtowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit. 2006;12:112-119.
5. 5. Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes. 2009 Dec;58(12):2731-40.
6. 6. Kershaw EE, Flier JS. Adipose tissue is an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–56.
7. 7. Riva M, Nitert MD, Voss U, Sathanoori R, Lindqvist A, Ling C, et al. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell Tissue Res. 2011 Dec;346(3):393-405.
8. 8. Gonzalez R, Perry RL, Gao X, Gaidhu MP, Tsushima RG, Ceddia RB, et al. Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats. Endocrinology. 2011;152:3628-37.

9. 9. Isıldak M, Sain Güven G, Gürlek A. Metabolik sendrom ve insulin direnci Hacettepe Tıp Dergisi 2004;35:96-9.
10. 10. Endokrinoloji Metabolizma ve Diabet. Özata M, Yönem A. (Editörler). 1. baskı. İstanbul Medical Yayıncılık; 2006: 550-63.
11. 11. METABOLİK SENDROM KILAVUZU © Türkiye Endokrinoloji ve Metabolizma Derneği • 2009
12. 12. Avi Ben-Haroush, Yariv Y, Benjamin F. Insulin resistance and metformin in polycystic ovary syndrome. Eur J of Obstet Gynecol and Reprod Biology 2004;115:125-33.
13. 13. Cibula D, Cifkova R, Fanta M, Polende R, Zivny J, Skibova J. Increased risk of NIDDM, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785-789.
14. 14. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology, 2005;146:1764–71.
15. 15. Heinonen MV, Purhonen AK, Miettinen P, Pääkkönen M, Pirinen E, Alhava E, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept. 2005 Aug 15;130(1-2):7-13.
16. 16. Altinkaya SÖ, Nergiz S, Küçük M, Yüksel H. Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014 May;176:168-72.
17. 17. Benk Silfeler D, Gokce C, Keskin Kurt R, Yilmaz Atilgan N, Ozturk OH, Turhan E, et al. Does polycystic ovary syndrome itself have additional effect on apelin levels? Obstet Gynecol Int. 2014;2014:536896.
18. 18. Lee DK, George SR, O'Dowd BF. Unraveling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 2006;27:190-194.
19. 19. Ademoglu EN, Gorar S, Carlıoglu A, Yazıcı H, Dellal FD, Berberoglu Z, et al. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest. 2014 Aug;37(8):715-9.
20. 20. Deniz R, Gurates B, Aydin S, Celik H, Sahin I, Baykus Y, et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine. 2012;42:694-9.
21. 21. Hamburg R. Management of polycystic ovary syndrome in adolescence. Reviews in Gynecological Practice 2004;4:148-155.
22. 22. Shimizu H, Oh-I S, Okada S, Mori M. Nesfatin-1: an overview and future clinical application. Endocr J. 2009;56:537-543.
23. 23. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007 Oct;148(10):4687-94.
24. 24. Ademoglu E, Berberoglu Z, Carlioglu A, Dellal F, Gorar S, Alphan Z, et al. Higher levels of circulating chemerin in both lean and obese patients with polycystic ovary syndrome. Minerva Ginecol. 2014 Dec;66:535-42.
25. 25. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995;98:27-32.
26. 26. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003;24:302-12.
27. 27. Creatsa M, Armeni E, Stamatelopoulos K, Rizos D, Georgiopoulos G, Kazani M, et al. Circulating androgen levels are associated with subclinical atherosclerosis and arterial stiffness in healthy recently menopausal women. Metabolism. 2012;61:193-201.